AtomVie Global Radiopharma is building a new radiopharmaceutical manufacturing facility at 10 Aeropark Blvd. in Hamilton, Canada. Credit : Panattoni Development Company (CNW Group/AtomVie Global Radiopharma Inc.)
HAMILTON, Ontario — December 3, 2025 — Ontario’s life sciences sector is set for a major boost as AtomVie Global Radiopharma (AtomVie) announces a $138 million investment to significantly expand radiopharmaceutical manufacturing in Hamilton. The project includes a new state-of-the-art facility that will increase AtomVie’s production capacity by more than tenfold, supporting the global demand for radiotherapeutics used in targeted cancer treatments.
The expansion strengthens Ontario’s position as a world leader in the radiopharmaceutical industry, leveraging the province’s unmatched medical isotope infrastructure and growing community of life sciences innovators.
Scaling Production to Meet Global Demand for Cancer Therapies
Global demand for radiopharmaceuticals—particularly targeted radiotherapeutics—is rapidly accelerating, outpacing current global manufacturing capability. AtomVie, a world-leading contract development and manufacturing organization (CDMO), is uniquely positioned to meet that need with advanced expertise and scalable production for clinical and commercial drug programs.
The company’s new Hamilton facility will support multi-product manufacturing and integrate seamlessly with Ontario’s well-established radioisotope network. The facility will supply radiopharmaceuticals for international clinical trials and commercial programs, helping deliver life-saving cancer treatments to patients in Canada and worldwide.
“We are proud to make this significant investment in Ontario’s life sciences ecosystem… Ontario’s strong nuclear medicine infrastructure and growing radiopharmaceutical community make it the ideal home for this next phase of growth,” said Bruno Paquin, CEO of AtomVie.
Patrick Lim, CFO of AtomVie, added:
“Our investment reflects AtomVie’s long-term commitment to global radiopharmaceutical supply and to Ontario as a centre of excellence… These resources will help accelerate construction, create high-quality jobs, and enhance Canada’s leadership in this rapidly growing sector.”
Ontario Strengthens Its Leadership in Radiopharmaceutical Innovation
Radiotherapeutics—highly targeted radioactive drugs that destroy cancer cells with minimal damage to surrounding tissue—represent one of the fastest-growing fields in oncology. AtomVie’s expansion supports the rising demand for these therapies and reinforces Ontario’s complete, vertically integrated isotope supply chain.
“AtomVie’s investment is terrific news for Hamilton workers and strengthens Ontario’s position as a global leader in the production and delivery of radiopharmaceuticals,” said the Hon. Vic Fedeli, Minister of Economic Development, Job Creation and Trade. “With global demand for targeted therapies rising, AtomVie’s expanded facility adds a critical link to our province’s life sciences supply chain.”
Ontario’s radiopharmaceutical ecosystem spans Hamilton, London, Toronto, and Eastern Ontario, supported by world-class academic institutions, research hospitals, and a deep pool of highly skilled talent.
Economic Impact and Government Support
The $138 million investment is expected to create 70 new high-quality jobs. Pending final agreement, the expansion will be supported by a grant of up to $5 million through the Invest Ontario Fund.
“We’re proud to work with a homegrown leader on this strategic expansion, which would strengthen Ontario’s role as a reliable supply-chain partner in the growing global market for radiotherapeutics,” said Khawar Nasim, CEO of Invest Ontario.
Invest Ontario continues to champion projects that advance the province’s Life Sciences Strategy—strengthening biomanufacturing capacity, expanding R&D, and helping establish Ontario as a global hub for life sciences innovation.
About Invest Ontario
Invest Ontario is the dedicated investment attraction agency for the province, serving as a one-window partner for global businesses. With deep expertise in advanced manufacturing, life sciences, and technology, the agency supports strategic investments that drive job creation, economic growth, and global competitiveness.
Learn more at www.investontario.ca.
About AtomVie Global Radiopharma
AtomVie is a global leader in GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. As a full-service CDMO, the company offers scientific, technical, regulatory, and logistics expertise to support radiopharmaceutical development from early clinical studies through commercialization. AtomVie currently operates in more than 28 countries and is constructing a new 72,300-square-foot manufacturing facility scheduled to open in Q1 2026.
More information: https://www.atomvie.com/
